Enigma Diagnostics and GSK announced that they will collaborate in the development of tests and the commercialization of the platform ML of Enigma.
London and Oxford, England, August 10, 2011- / PRNewswire / – Enigma Diagnostics Limited (Enigma) and GlaxoSmithKline (GSK) today announced that they signed agreements to provide and market exclusively system Enigma ® ML in Europe and in other key countries designated, including the India, the Brazil and Russia. The agreements include Enigma to develop an initial range of breathing tests that they are used in the technological platform of reaction in PCR (PCR) in real time, and will offer GSK an opportunity to generate revenue from other developments of evidence on infectious diseases and other therapeutic areas relevant to its health care business.
The Enigma ® ML system has the potential to provide a result from a raw sample in less than 60 minutes in the place where it is needed. The new partnership significantly expands the scope of the Association by flu announced in July 2009 for the Enigma ® ML system and builds on the extensive expertise and heritage of GSK respiratory therapeutic area and expanded capabilities offered by the system Enigma ® ML.
According to the terms of this agreement, GSK will make another capital investment and a payment in advance payments related to the I & D and royalties on net sales of the resulting products. Other payments will be subject to great marketing achievements that suit.
John McKinley, President and CEO of Enigma, said: “this is an important collaboration and represents a major achievement for Enigma.” These agreements for development testing, marketing and supply boosting sales and the strength of marketing of far-reaching GSK with exclusive Enigma of care system in the place of care, which has potential uses in a number of human diseases. “This is a partnership that will provide the much needed ability to”examine and treat”for the management of infectious diseases”.
Eddie Gray, President of Pharmaceuticals Europe of GSK said: “GSK is committed to improving the lives of patients suffering from respiratory diseases and other, offering truly innovative solutions to health care, in order to improve the care of these vulnerable patient populations.” “Collaboration with Enigma provides GSK an opportunity to provide a more complete solution to the health community and improve the care of patients through the provision of rapid diagnostic tests and last generation”.
GlaxoSmithKline, one of the major pharmaceutical companies and caring for the health of the world that are supported by research, is committed to improving the quality of human life making it possible that people do more, feel better and live longer.
Enigma Diagnostics Limited & the Enigma ® ML system
Enigma specializes in developing platforms for molecular diagnostic tools fast next generation for decentralized environments and in the place of care. The first IVD instrument of Enigma is the Enigma ® ML system that offer raw samples for diagnostic tests of comparable results in less than 60 minutes and accuracy standards with reference laboratories. Enigma ML system operators do not require specialist training, which will enable the system to be used in a wide range of environments, both in developed and emerging with regard to health care. The company is developing outstanding instruments and assessment platforms to make quick diagnoses in the place of care, based on exclusive technologies that are supported by its extensive portfolio of intellectual property.
Reaction technology in PCR (PCR) is a diagnostic technique widely used and high specificity, in which a few copies of the target DNA are increased in their numbers to generate millions of copies of the specific DNA sequence, which facilitates the identification of the sample.
